Your browser doesn't support javascript.
Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
Nishikubo, Masashi; Shimomura, Yoshimitsu; Maruoka, Hayato; Nasu, Seiko; Nishioka, Tomomi; Sakizono, Kenji; Mitsuyuki, Satoshi; Kubo, Tomoyo; Okada, Naoki; Nakagawa, Daishi; Kamijo, Kimimori; Imoto, Hiroharu; Yamamoto, Ryusuke; Nagai, Yuya; Hiramoto, Nobuhiro; Yoshioka, Satoshi; Yonetani, Noboru; Matsushita, Akiko; Miyakoshi, Chisato; Doi, Asako; Ishikawa, Takayuki.
  • Nishikubo M; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Shimomura Y; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan; Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan. Electronic address: shimomura_0119@yahoo.co.jp.
  • Maruoka H; Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Nasu S; Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Nishioka T; LSI Medience Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Sakizono K; Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Mitsuyuki S; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Kubo T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Okada N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Nakagawa D; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Kamijo K; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Imoto H; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Yamamoto R; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Nagai Y; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Hiramoto N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Yoshioka S; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Yonetani N; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Matsushita A; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Miyakoshi C; Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Doi A; Department of Infectious Diseases, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
  • Ishikawa T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
J Infect Chemother ; 2022 Nov 26.
Article in English | MEDLINE | ID: covidwho-2233812
ABSTRACT

BACKGROUND:

The effectiveness of mRNA COVID-19 vaccines and the optimal timing of vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients remains inadequately investigated. We examine the effectiveness and safety of mRNA COVID-19 vaccines in allo-HSCT recipients.

METHOD:

This prospective observational study included 44 allo-HSCT recipients and 38 healthy volunteers. The proportion of subjects acquiring anti-S1 IgG antibodies were considered as the primary endpoint. The occurrence of adverse events after vaccination and objective deterioration of chronic graft-versus-host disease (GVHD) were defined as secondary endpoints. In addition, we compared the geometric mean titers (GMT) of anti-S1 antibody titers in subgroups based on time interval between transplantation and vaccination.

RESULTS:

A humoral response to the vaccine was evident in 40 (91%) patients and all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95% confidence interval [CI] 120-643) BAU/mL and 532 (95% CI 400-708) BAU/mL, respectively. (p = 0.603). A short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers. No serious adverse events and deterioration of chronic GVHD were observed. Only one case of new development of mild chronic GVHD was recorded.

CONCLUSION:

Messenger RNA COVID-19 vaccines induce humoral responses in allo-HSCT recipients and can be administered safely.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.11.010

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.11.010